Company Filing History:
Years Active: 2005-2006
Title: Innovations of Chrys-Ann Higginbotham
Introduction
Chrys-Ann Higginbotham is a notable inventor based in Columbia, MO (US). She has made significant contributions to the field of therapeutic and diagnostic radiopharmaceuticals. With a total of 2 patents, her work focuses on innovative methods for treating neoplastic diseases.
Latest Patents
Higginbotham's latest patents include the development of gastrin receptor-avid peptide conjugates. This compound is designed for use as a therapeutic or diagnostic radiopharmaceutical. It includes a group capable of complexing a medically useful metal attached to a moiety that binds to a gastrin-releasing peptide receptor. Additionally, she has devised a method for treating subjects with neoplastic diseases. This method involves administering an effective amount of a radiopharmaceutical that has a metal chelated with a chelating group. This group is attached to a moiety capable of binding to gastrin-releasing peptide receptors expressed on tumor cells, leading to subsequent internalization inside the cell. Furthermore, she has created a method for forming a therapeutic or diagnostic compound by reacting a metal synthon with a chelating group covalently linked to a moiety that binds to gastrin-releasing peptide receptors.
Career Highlights
Chrys-Ann Higginbotham is affiliated with the University of Missouri, where she continues her research and development in the field of radiopharmaceuticals. Her innovative work has the potential to significantly impact cancer treatment and diagnostics.
Collaborations
Some of her notable coworkers include Timothy J. Hoffman and Wynn A. Volkert. Their collaborative efforts contribute to advancing research in the field.
Conclusion
Chrys-Ann Higginbotham's contributions to the field of radiopharmaceuticals exemplify the importance of innovation in medical science. Her patents and ongoing research hold promise for improving treatment options for patients with neoplastic diseases.